Leveraging Electron Beam (eBeam) Technology for Advancing the Development of Inactivated Vaccines

Authors:
Open Access
Publisher website
Google Scholar
Abstract
This review provides an overview of electron beam (eBeam) technology and its applications across a wide variety of disciplines. More importantly, it discusses this technology’s advantages and its benefits in developing inactivated vaccines. eBeam technology is currently being used all around the world for a variety of industrial applications, extending from food pasteurization to the cross-linking of polymers in the wire and cable industries. It is a successful emerging alternative for developing vaccines against bacterial, protozoan, and viral pathogens. This review includes a descriptive account of the mechanism of action of eBeam and how this technology achieves the complete inactivation of pathogens while retaining the integrity of their surface epitopes. This unique advantage is crucial for the production of efficacious vaccines. This review provides a detailed account of the usage of eBeam technology for developing vaccines to protect a multitude of hosts against a wide range of pathogens. eBeam-inactivated vaccines are advantageous over live vaccines, RNA/subunit vaccines, and chemically inactivated vaccines mainly due to the complete inactivation of pathogens, and the presence of intact, highly antigenic epitopes. To conclude, this article descriptively highlights eBeam technology’s advantages over other means of vaccine development.
Funding Information
  • Agriculture and Food Research Initiative Competitive (2024-67015-42629, Round 16, 58-0402-9-215, AWD-103128, GR018362)
  • USDA National Institute of Food and Agriculture, USDA-ARS Innovation Funds (2024-67015-42629, Round 16, 58-0402-9-215, AWD-103128, GR018362)
  • US Poultry & Egg Harold E. Ford Foundation (2024-67015-42629, Round 16, 58-0402-9-215, AWD-103128, GR018362)

This publication has 97 references indexed in Scilit: